Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD.

Jiraporn JitprapaikulsanJames P FryerMasoud MajedCarin Y SmithSarah M JenkinsPhilippe CabreShannon R HinsonBrian G WeinshenkerJay MandrekarJohn J ChenClaudia F LucchinettiYujuan JiaoJessica SeganJohn E SchmelingJohn MillsEoin P FlanaganAndrew McKeonSean J Pittock

Published in: Neurology(R) neuroimmunology & neuroinflammation (2020)

This study provides Class II evidence that in patients with NMOSD, AQP4-IgG titers and measures of complement-mediated cell killing activity do not predict relapses, relapse severity, or disability.

Keyphrases

single cell
cell therapy
multiple sclerosis
stem cells
mesenchymal stem cells
bone marrow